David Griffin 🦠🧫💉
@drdavidwjg.bsky.social
1K followers 780 following 40 posts
👨🏼‍🎓BSc, MBBS, MPH, FRACP👨🏼‍⚕️ Infectious Diseases Doc, PhD Candidate. Interests: #HIV, #BBV, #TxID, #IPC, #Vaccines #IDSky #HIVSky Auch auf Deutsch verfügbar. 🇦🇺🇩🇪🏳️‍🌈 he/him
Posts Media Videos Starter Packs
drdavidwjg.bsky.social
2/

#HIV has minimal influence on organ allocation in respondents, but is a significant barrier to the selection of a potential donor, even an appropriate recipient. Organ quality was the most influential factor in selection of a prospective donor.
drdavidwjg.bsky.social
Pleased to share results of our discrete choice experiment of the influence of HIV on organ procurement and allocation in Australia #HIVAIDS2025

#healthequity #IDsky #HIVsky #TxIDsky #PhD
drdavidwjg.bsky.social
Important #latebreaker study at #CROI2025 SCORPIO-PEP phase III RCT showed ensitrelvir (Day 1: 375mg, Day 2-5: 125mg) reduced PCR positive, symptomatic #COVID19 in HHC if started w/in 72 hrs of index case symptomatic C19 by 67%. Including in those with high risk progression. Need ICH and RACF data!
Reposted by David Griffin 🦠🧫💉
juanmichaelii.bsky.social
Calling Our Patients “High Risk” Hurts Them

"Being called risky or associated w risk b/c of your sexual health decisions makes most people feel ashamed. And that shame is nothing more than another barrier to care. "

A banger op-ed by @jncherabiemd.bsky.social
www.thebodypro.com/hiv/calling-...
www.thebodypro.com
Reposted by David Griffin 🦠🧫💉
jama.com
JAMA @jama.com · Nov 28
Cervical cancer mortality in US women younger than 25 years significantly declined between 2016 and 2021, likely due to the widespread adoption of HPV vaccination.

ja.ma/4i9ghPC
drdavidwjg.bsky.social
Ten Americas: a systematic analysis of life expectancy disparities in the USA - @thelancet.bsky.social

Somber update on the 8 Americas study; highlights growing inequities in life expectancy, impact of structural racism and disproportionate impact of #COVID19

www.thelancet.com/journals/lan...
drdavidwjg.bsky.social
Dr Eloise Williams gave an important update confirmatory testing for #HIV in Australia.

#MicroSky #HIVsky #IDsky
#HIVinFocus

- Use of accredited NAAT in diagnostics (cf monitoring) on separate sample to initial serology
- p24 Ag immunoassay (no longer available)
- (traditional) western blot
drdavidwjg.bsky.social
Vikas Parwani from HIV/AIDS Legal Center shares a brief insight into immigration to Aus for #PWH.

Immigration exempt from discrimination laws that protect #PWH.

#HIV can be barrier due to perceived cost, but opportunities for ‘health waiver’ exist. HIV not the only barrier #PWH face. #HIVinFocus
drdavidwjg.bsky.social
None, though I don’t have many people on injectables at this stage.

I think more will be inclined to switch, once LAI are Q6M, or can be self administered. (LEN + ? 👀)

Frequent clinical attendance and frequent injections seem major deterrents.

Cab-LA not yet funded as PrEP here either.
drdavidwjg.bsky.social
A/Prof. Mina John from Royal Perth Hospital, presents Western Australian data on implementation LAI ART in hard to reach populations, mirroring #UCSF data; improved retention in care and virological suppression.

Multiple other benefits.

#HIVsky #IDsky
drdavidwjg.bsky.social
👍🏼

Same! (Plus Simva-, and Pravastatin, thou not sure why anyone would use these preferentially…)

We have:
Rosuvastatin 5-40mg
Atorvastatin 10-80mg

I typically start with rosuvastatin 10mg, unless pt on boosted PI (then typically half)
drdavidwjg.bsky.social
Do you have access to pitavastatin?
drdavidwjg.bsky.social
Interesting!

We use www.cvdcheck.org.au/calculator which is based on the NZ PREDICT-1° equation.

I mostly use it in conversations about risk and impact of risk factor modification (eg smoking cessation). None of our calculators incorporate HIV, ART, etc, and likely underestimate risk.
Australian cardiovascular disease risk calculator | AusCVDRisk
www.cvdcheck.org.au
drdavidwjg.bsky.social
3/ #HIVinFocus

International guidelines recommend implementing the #Reprievestudy findings with different thresholds of #CVD risk statin therapy.

Australian guidance most closely aligns with the EACS recommendation.
drdavidwjg.bsky.social
2/ Australian CVD risk calculators typically assign a lower risk to #PWH than AHA/ACC score.

International guidelines recommend implementing this evidence differently.
drdavidwjg.bsky.social
A/Prof Janine Trevillyan from #AustinHealth describes the challenges of applying the #REPRIEVEstudy in Australia; we don’t have pitavastatin and use different risk calculators. #IDsky #HIVsky

Atorva- and rosuvastatin reduce surrogates of CVD risk, though choosing ideal biomarker can be challenging.
drdavidwjg.bsky.social
6/ #REPRIEVEstudy also highlighted that #CVD risk calculators tend to overestimate CVD risk in developing countries, but underestimate risk in women.
drdavidwjg.bsky.social
5/ #REPRIEVEstudy showed that statins were safe (pitavastatin was chosen because it doesn’t interact with PIs), with a non-sig trend towards incident #diabetes, though glycaemic control was curiously unchanged.
drdavidwjg.bsky.social
4/ #REPRIEVEstudy demonstrated definitively that statins reduce CVD risk in people with #HIV 35% with low to moderate #ASCVD risk at baseline.
drdavidwjg.bsky.social
3/ mechanistically statins reduce CVD risk through several mechanisms; LDL lowering, plaque stabilization, dampening inflammation. Interestingly #REPRIEVEstudy proteomic analysis suggested PCOLCE may be important in pitavastatin impact on collagen deposition.
drdavidwjg.bsky.social
2/ importance of identifying and addressing lifestyle factors, social and psychological determinants of health to reduce #CVD risk
drdavidwjg.bsky.social
Day 2 #HIVinFocus

Prof. Currier from #UCLA offering insights into CVD risk in #PWH.

First, association between clonal hematopoiesis and #CVD risk in #HIV demonstrated in several cohorts.